173 related articles for article (PubMed ID: 9217352)
1. Higher incidence of viable Mycobacterium leprae within the nerve as compared to skin among multibacillary leprosy patients released from multidrug therapy.
Shetty VP; Suchitra K; Uplekar MW; Antia NH
Lepr Rev; 1997 Jun; 68(2):131-8. PubMed ID: 9217352
[TBL] [Abstract][Full Text] [Related]
2. Persistence of Mycobacterium leprae in the peripheral nerve as compared to the skin of multidrug-treated leprosy patients.
Shetty VP; Suchitra K; Uplekar MW; Antia NH
Lepr Rev; 1992 Dec; 63(4):329-36. PubMed ID: 1479872
[TBL] [Abstract][Full Text] [Related]
3. Presence of M. leprae in tissues in slit skin smear negative multibacillary (MB) patients after WHO-MBR.
Sharma A; Sharma VK; Rajwanshi A; Das A; Kaur I; Kumar B
Lepr Rev; 1999 Sep; 70(3):281-6. PubMed ID: 10603717
[TBL] [Abstract][Full Text] [Related]
4. The effect of corticosteroids usage on bacterial killing, clearance and nerve damage in leprosy; part 3--Study of two comparable groups of 100 multibacillary (MB) patients each, treated with MDT + steroids vs. MDT alone, assessed at 6 months post-release from 12 months MDT.
Shetty VP; Khambati FA; Ghate SD; Capadia GD; Pai VV; Ganapati R
Lepr Rev; 2010 Mar; 81(1):41-58. PubMed ID: 20496569
[TBL] [Abstract][Full Text] [Related]
5. Viability of Mycobacterium leprae in skin and peripheral nerves and persistence of nerve destruction in multibacillary patients after 2 years of multidrug therapy.
Job CK; Jayakumar J; Aschhoff M; Mathan MM
Int J Lepr Other Mycobact Dis; 1996 Mar; 64(1):44-50. PubMed ID: 8627112
[TBL] [Abstract][Full Text] [Related]
6. Are viable Mycobacterium leprae present in lepromatous patients after completion of 12 months' and 24 months' multi-drug therapy?
Ebenezer GJ; Daniel S; Norman G; Daniel E; Job CK
Indian J Lepr; 2004; 76(3):199-206. PubMed ID: 15835604
[TBL] [Abstract][Full Text] [Related]
7. Viability and drug sensitivity of M. leprae isolated from long-term WHO/MDT treated multibacillary leprosy patients.
Habtemariam H
Lepr Rev; 1999 Mar; 70(1):43-6. PubMed ID: 10405543
[No Abstract] [Full Text] [Related]
8. In leprosy the presence of mycobacteria in the nerve is an essential factor in the cycle and spectrum of Mycobacterium leprae infection.
Negesse Y; Beimnet K; Miko T; Wondimus A; Berhan TY
Lepr Rev; 1993 Jun; 64(2):104-9. PubMed ID: 8341112
[TBL] [Abstract][Full Text] [Related]
9. Nasal mucosa and skin of smear-positive leprosy patients after 24 months of fixed duration MDT: histopathological and microbiological study.
Ebenezer GJ; Job A; Abraham S; Arunthathi S; Rao PS; Job CK
Int J Lepr Other Mycobact Dis; 1999 Sep; 67(3):292-7. PubMed ID: 10575409
[TBL] [Abstract][Full Text] [Related]
10. Detection of viable organisms in leprosy patients treated with multidrug therapy.
Gupta UD; Katoch K; Singh HB; Natrajan M; Sharma VD; Katoch VM
Acta Leprol; 1999; 11(3):89-92. PubMed ID: 10544720
[TBL] [Abstract][Full Text] [Related]
11. Comment: Persistence of Mycobacterium leprae in the peripheral nerves of multidrug-treated leprosy patients.
Grange JM; Beck JS; Abbot NC
Lepr Rev; 1993 Sep; 64(3):280. PubMed ID: 8110236
[No Abstract] [Full Text] [Related]
12. Skin, dartos, and nerve biopsies as aids to diagnosis in leprosy.
Pandya NJ
Plast Reconstr Surg; 1974 Jul; 54(1):70-80. PubMed ID: 4598943
[No Abstract] [Full Text] [Related]
13. [Neurological manifestations of leprosy].
Grimaud J; Vallat JM
Rev Neurol (Paris); 2003 Nov; 159(11):979-95. PubMed ID: 14710019
[TBL] [Abstract][Full Text] [Related]
14. Comparison of PCR mediated amplification of DNA and the classical methods for detection of Mycobacterium leprae in different types of clinical samples in leprosy patients and contacts.
Torres P; Camarena JJ; Gomez JR; Nogueira JM; Gimeno V; Navarro JC; Olmos A
Lepr Rev; 2003 Mar; 74(1):18-30. PubMed ID: 12669929
[TBL] [Abstract][Full Text] [Related]
15. Childhood leprosy in a tertiary-care hospital in Delhi, India: a reappraisal in the post-elimination era.
Singal A; Sonthalia S; Pandhi D
Lepr Rev; 2011 Sep; 82(3):259-69. PubMed ID: 22125934
[TBL] [Abstract][Full Text] [Related]
16. A 6 week quadruple drug regimen for the treatment of multibacillary leprosy.
Pattyn S; Grillone S
Lepr Rev; 2000 Mar; 71(1):43-6. PubMed ID: 10820986
[No Abstract] [Full Text] [Related]
17. A study on the impact of FD-MDT on 200 leprosy patients.
Vara N; Marfatiya Y
Indian J Lepr; 2005; 77(3):217-27. PubMed ID: 16353520
[TBL] [Abstract][Full Text] [Related]
18. Drug resistance patterns in Mycobacterium leprae isolates from relapsed leprosy patients attending The Leprosy Mission (TLM) Hospitals in India.
Lavania M; Jadhav RS; Chaitanya VS; Turankar R; Selvasekhar A; Das L; Darlong F; Hambroom UK; Kumar S; Sengupta U
Lepr Rev; 2014 Sep; 85(3):177-85. PubMed ID: 25509718
[TBL] [Abstract][Full Text] [Related]
19. Leprosy. An update: definition, pathogenesis, classification, diagnosis, and treatment.
Eichelmann K; González González SE; Salas-Alanis JC; Ocampo-Candiani J
Actas Dermosifiliogr; 2013 Sep; 104(7):554-63. PubMed ID: 23870850
[TBL] [Abstract][Full Text] [Related]
20. Relapses in multibacillary leprosy patients after multidrug therapy.
Poojabylaiah M; Marne RB; Varikkodan R; Bala N; Dandakeri S; Martis J
Lepr Rev; 2008 Sep; 79(3):320-4. PubMed ID: 19009982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
